Detail akcie Exelixis online

Business Summary: Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Financial Summary: BRIEF: For the fiscal year ended 03 January 2025, Exelixis Inc revenues increased 18% to $2.17B. Net income increased from $207.8M to $521.3M. Revenues reflect CABOMETYX segment increase of 11% to $1.8B, License revenues segment increase of 96% to $349.2M, U.S segment increase of 11% to $1.82B, Europe segment increase from $145M to $318.6M. Net income benefited from Other Research and development decrease of 17% to $695.8M (expense).